Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > Intensive co-located smoking cessation programme highly effective during lung screening

Intensive co-located smoking cessation programme highly effective during lung screening

Presented By
Prof. Rachael Murray, University of Nottingham, UK
WCLC 2022

Co-located smoking cessation support during a lung health check leads to high abstinence rates in participants, especially when this 1-on-1 supportive care is continued for several months. In addition, women appear to benefit from additional supportive communication and individualised feedback, the randomised YESS trial indicated [1].

“The addition of tobacco treatment to lung cancer screening reduces deaths by an additional 14%, providing a fantastic opportunity to make real health gains [2],” argued Prof. Rachael Murray (University of Nottingham, UK). “However, it remains unclear what type of smoking cessation intervention will elicit the largest effect.” The current study invited 2,150 eligible participants who were scheduled for a lung health check to visit a co-located smoking cessation practitioner (SCP) through an opt-out system. Of the eligible participants, 1,609 agreed to receive ongoing support by the SCP and 1,003 were randomised into the YESS trial (NCT03750110). In the control arm, participants received behavioural support plus pharmacotherapy (n=476), whereas participants in the intervention arm (n=527) received the support of the control arm plus personalised feedback and supportive communication. After 4 weeks, 3 months, and 12 months, smoking status was assessed (7-day validated point prevalence).

Abstinence from smoking was 16.5% after 4 weeks, between 30.0–33.6% after 3 months, and between 28.6–29.2% after 12 months of support by the SCP, with no significant differences between the control group and the intervention group. However, a significant interaction effect was observed for sex after 3 months; the intervention with personalised supportive care appeared to be more effective in women than in men (OR 1.70 vs 0.82; P=0.002); this effect was maintained at 12 months. Prof. Murray highlighted that cessation rates around 30% are high, which indicates the benefit of co-located and ongoing smoking support. Also, cessation rates are higher after 3 months than after 4 weeks, suggesting that participants may not be ready to quit smoking at the time of the lung health check, but that continued support by an SCP leads to high cessation rates in time.

  1. Murray RL, et al. Adding co-located, personalised stop smoking support to a lung cancer screening programme: The Yorkshire Enhanced Stop Smoking study (YESS). PL03.03, WCLC 2022, Vienna, Austria, 06–09 August.
  2. Cao P, et al. J Thorac Oncol. 2020 Jul;15(7):1160-1169.


Copyright ©2022 Medicom Medical Publishers

Posted on